Emily Y. Chu

Emily Y. Chu

Auto-generated profile, based on publicly available information

Emily Y. Chu

Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2012 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
ECEmily Y. Chu
Emily Y. Chu
KWKarolyn A. Wanat
Karolyn A. Wanat
CMChristopher J. Miller
Christopher J. Miller
RARavi K. Amaravadi
Ravi K. Amaravadi
LFLeslie A. Fecher
Leslie A. Fecher
MRMisha Rosenbach
Misha Rosenbach

1 January 2012 in Archives of Dermatology
Verified
Journal Article
Open access
PDF file
ECEmily Y. Chu
Emily Y. Chu
AFAlexandra F. Freeman
Alexandra F. Freeman
HJHuie Jing
Huie Jing
ECEdward W. Cowen
Edward W. Cowen
JDJoie Davis
Joie Davis
MTMaria L. Chanco Turner
Maria L. Chanco Turner
BackgroundMutations in the dedicator of cytokinesis 8 gene (DOCK8) cause a combined primary immunodeficiency syndrome that is characterized by elevated serum IgE levels, depressed IgM levels, eosinophilia, sinopulmonary infections, cutaneous viral infections, and lymphopenia. Many patients with DOCK8 deficiency were previously thought to have a variant of Job's syndrome. Distinguishing between DOCK8 deficiency and Job's syndrome, also referred to as autosomal dominant hyper-IgE syndrome, on the basis of clinical findings alone is challenging. The discovery of the DOCK8 mutation has made it possible to differentiate the cutaneous manifestations of these hyper-IgE syndromes.ObservationsTwenty-one patients from 14 families with confirmed homozygous or compound heterozygous mutations in DOCK8 were evaluated. Clinical findings included dermatitis, asthma, food and environmental allergies, recurrent sinopulmonary infections, staphylococcal skin abscesses, and severe cutaneous viral infections. Malignant neoplasms, including aggressive cutaneous T-cell lymphoma, anal and vulvar squamous cell carcinomas, and diffuse large B-cell lymphoma, developed in 5 patients during adolescence and young adulthood.ConclusionsDOCK8 deficiency and Job's syndrome share several clinical features, including elevated serum IgE levels, dermatitis, recurrent sinopulmonary infections, and cutaneous staphylococcal abscesses. However, the presence of recalcitrant, widespread cutaneous viral infections, asthma, and food and environmental allergies, as well as the absence of newborn rash and coarse facies, favors the clinical diagnosis of DOCK8 deficiency. Rates of malignancy and overall mortality in patients with DOCK8 deficiency were higher than in those with Job's syndrome, highlighting the value of distinguishing between these conditions and the importance of close monitoring for neoplasia.

1 June 2016 in Journal of Cutaneous Pathology
Verified
Journal Article
Closed access
PDF file
MMMark C. Mochel
Mark C. Mochel
MMMichael E. Ming
Michael E. Ming
SISotonye Imadojemu
Sotonye Imadojemu
TGTara C. Gangadhar
Tara C. Gangadhar
LSLynn M. Schuchter
Lynn M. Schuchter
ECEmily Y. Chu
Emily Y. Chu

1 May 2013 in JAMA Dermatology
Verified
Journal Article
Closed access
MRMisha Rosenbach
Misha Rosenbach
HYHowa Yeung
Howa Yeung
ECEmily Y. Chu
Emily Y. Chu
EKEllen J. Kim
Ellen J. Kim
APAimee S. Payne
Aimee S. Payne
JGJoel M. Gelfand
Joel M. Gelfand
A validated scoring system is essential to assess the effect of therapeutic interventions on a disease. The instrument introduced here captures sarcoidosis disease activity in a reliable, reproducible manner, which will help standardize clinical trial outcomes and allow comparative efficacy studies in the future and may help lead to more robust data regarding the effect of different treatments on cutaneous sarcoidosis. To assess the reliability and convergent validity of the Cutaneous Sarcoidosis Activity and Morphology Instrument (CSAMI) and Sarcoidosis Activity and Severity Index (SASI) for evaluating cutaneous sarcoidosis outcomes. Cross-sectional study evaluating cutaneous sarcoidosis disease severity using CSAMI, SASI, and Physician's Global Assessment (PGA) as reference in the dedicated cutaneous sarcoidosis clinic of a teaching hospital. Eight dermatologists evaluating cutaneous sarcoidosis in 11 patients. Evaluation using the study instruments. Primary outcomes included interrater and intrarater reliability and convergent validity; secondary outcomes, correlation with quality-of-life measures and time required for completion. All instruments demonstrated good to excellent intrarater reliability. Interrater reliability was excellent for CSAMI Activity scores (intraclass correlation coefficient, 0.82 [95% CI, 0.66-0.94]) and fair to poor for CSAMI Damage scores (0.42 [0.21-0.72]), modified Facial SASI (0.40 [0.17-0.72]), and PGA scores (0.40 [0.18-0.70]). CSAMI Activity and Damage scores and modified Facial SASI all demonstrated convergent validity with statistically significant correlations with PGA scores. Trends for correlations were seen between CSAMI scores and specific Skindex-29 quality-of-life domains. Although CSAMI required longer time to complete than SASI, both were scored within adequate time for use in clinical trials. CSAMI appears to be a reliable and valid outcome instrument to measure cutaneous sarcoidosis and may capture a wide range of body surface and cutaneous morphologic types. This instrument can be adopted into clinical practice and clinical trials to allow physicians to assess the intensity of their patients' cutaneous sarcoidosis disease activity. Widespread use of one metric for disease severity assessment can help standardize the evaluation of the effect of various treatments on the disease. Future research is necessary to demonstrate its sensitivity to change and to confirm its correlation with quality-of-life measures.

10 November 2017 in Journal of Cutaneous Pathology
Verified
Journal Article
Closed access
PDF file
KSKimberly Shao
Kimberly Shao
SMSuzanne McGettigan
Suzanne McGettigan
RERosalie Elenitsas
Rosalie Elenitsas
ECEmily Y. Chu
Emily Y. Chu

20 March 2025 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MSMichael R. Sargen
Michael R. Sargen
RBRaymond L. Barnhill
Raymond L. Barnhill
DEDavid E. Elder
David E. Elder
SSSusan M. Swetter
Susan M. Swetter
VPVictor G. Prieto
Victor G. Prieto
BSBrittani Seynnaeve
Brittani Seynnaeve
PURPOSE: The purpose of this study was to develop recommendations for the diagnostic evaluation and surgical management of cutaneous melanoma (CM) and atypical Spitz tumors (AST) and non-Spitz melanocytic tumors (melanocytomas) in pediatric (age 0-10 years) and adolescent (age 11-18 years) patients. METHODS: A Children's Oncology Group–led panel with external, multidisciplinary CM specialists convened to develop recommendations on the basis of available data and expertise. RESULTS: Thirty-three experts from multiple specialties (cutaneous/medical/surgical oncology, dermatology, and dermatopathology) established recommendations with supporting data from 87 peer-reviewed publications. RECOMMENDATIONS: (1) Excisional biopsies with 1-3 mm margins should be performed when feasible for clinically suspicious melanocytic neoplasms. (2) Definitive surgical treatment for CM, including wide local excision and sentinel lymph node biopsy (SLNB), should follow National Comprehensive Cancer Network Guidelines in the absence of data from pediatric-specific surgery trials and/or cohort studies. (3) Accurate classification of ASTs as benign or malignant is more likely with immunohistochemistry and next-generation sequencing. (4) It may not be possible to classify some ASTs as likely/definitively benign or malignant after clinicopathologic and/or molecular correlation, and these Spitz tumors of uncertain malignant potential should be excised with 5 mm margins. (5) ASTs favored to be benign should be excised with 1- to 3-mm margins if transected on biopsy. (6) Re-excision is not necessary if the AST does not extend to the biopsy margin(s) when complete/excisional biopsy was performed. (7) SLNB should not be performed for Spitz tumors unless a diagnosis of CM is favored on clinicopathologic evaluation. (8) Non-Spitz melanocytomas have a presumed increased risk for progression to CM and should be excised with 1- to 3-mm margins if transected on biopsy. (9) Re-excision of non-Spitz melanocytomas is not necessary if the lesion is completely excised on biopsy.